Figure 2 | Scientific Reports

Figure 2

From: Real-time metabolic profiling of oesophageal tumours reveals an altered metabolic phenotype to different oxygen tensions and to treatment with Pyrazinib

Figure 2

Pyrazinib (P3) significantly reduces OCR in OAC treatment-naïve biopsies. OCR and ECAR were measured in real-time using Seahorse Biosciences XFe24 analyser. (A) Percentage change from baseline of OCR following treatment with 0.1% DMSO control, 10 µM Pyrazinib (P3) or 6 µM Oligomycin for 24 h, (n = 10), Wilcoxon paired t-test, *p < 0.05. (B) Percentage change from baseline of ECAR following treatment with 0.1% DMSO control, 10 µM Pyrazinib (P3) or 6 µM Oligomycin for 24 h, (n = 10), Wilcoxon paired t-test. Data are expressed as + SEM.

Back to article page